Động lực học số lượng tiểu cầu sớm có giá trị tiên đoán trong hội chứng loạn sản tủy ít nguy cơ

Greenberg, 1997, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, 2079, 10.1182/blood.V89.6.2079 Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, 2454, 10.1182/blood-2012-03-420489 Alhan, 2016, The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system, Leukemia, 30, 658, 10.1038/leu.2015.295 Bejar, 2012, Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes, J Clin Oncol, 30, 3376, 10.1200/JCO.2011.40.7379 Pellagatti, 2013, Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes, J Clin Oncol, 31, 3557, 10.1200/JCO.2012.45.5626 Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696 Montillo, 2005, Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies, Haematologica, 90, 391 Petrylak, 2006, Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16, J Natl Cancer Inst, 98, 516, 10.1093/jnci/djj129 de Swart, 2015, Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry, Br J Haematol, 170, 372, 10.1111/bjh.13450 Vardiman, 2002, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, 2292, 10.1182/blood-2002-04-1199 de Swart, 2017, Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance, Ann Hematol, 96, 1105, 10.1007/s00277-017-3009-7 Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making, J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038 Korn, 1986, Censoring distributions as a measure of follow-up in survival analysis, Stat Med, 5, 255, 10.1002/sim.4780050306 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Akaike, 1974, A new look at the statistical model identification, IEEE Trans Automat Contr, 19, 716, 10.1109/TAC.1974.1100705 Grambsch, 1994, Statistical analysis of proliferative index data in clinical trials, Stat Med, 13, 1619, 10.1002/sim.4780131603 O’Brien, 2007, A caution regarding rules of thumb for variance inflation factors, Qual Quant, 41, 673, 10.1007/s11135-006-9018-6 Friedman, 2010, Regularization paths for generalized linear models via coordinate descent, J Stat Softw, 33, 1, 10.18637/jss.v033.i01 Costongs, 1985, Short-term and long-term intra-individual variations and critical differences of haematological laboratory parameters, J Clin Chem Clin Biochem, 23, 69 Buckley, 2000, A novel approach to the assessment of variations in the human platelet count, Thromb Haemost, 83, 480, 10.1055/s-0037-1613840 Ross, 1988, Stability of hematologic parameters in healthy subjects. Intraindividual versus interindividual variation, Am J Clin Pathol, 90, 262, 10.1093/ajcp/90.3.262 Garcia-Manero, 2008, A prognostic score for patients with lower risk myelodysplastic syndrome, Leukemia, 22, 538, 10.1038/sj.leu.2405070 Goldberg, 2010, Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries, J Clin Oncol, 28, 2847, 10.1200/JCO.2009.25.2395 Nachtkamp, 2016, Causes of death in 2877 patients with myelodysplastic syndromes, Ann Hematol, 95, 937, 10.1007/s00277-016-2649-3 Dayyani, 2010, Cause of death in patients with lower-risk myelodysplastic syndrome, Cancer, 116, 2174 Neukirchen, 2009, Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes, Eur J Haematol, 83, 477, 10.1111/j.1600-0609.2009.01299.x Sekeres, 2008, Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes, J Clin Oncol, 26, 5943, 10.1200/JCO.2007.15.5770 van der Helm, 2011, Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme, Br J Haematol, 155, 599, 10.1111/j.1365-2141.2011.08893.x Zeidan, 2014, Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS, Br J Haematol, 167, 62, 10.1111/bjh.13008 Pereira, 2011, Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support, Am J Hematol, 86, 245, 10.1002/ajh.21959 Zhao, 2017, Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model, PLoS One, 12, e0180756, 10.1371/journal.pone.0180756 Ibrahim, 2010, Basic concepts and methods for joint models of longitudinal and survival data, J Clin Oncol, 28, 2796, 10.1200/JCO.2009.25.0654